Study | Population | Treatment/Duration | SVR12 rates |
---|---|---|---|
ION-1 | HCV GT1 treatment-naïve including 15.7% (136/865) with cirrhosis | SOF/LDV, 12 weeks | 97.7% (209/214) |
SOF/LDV + RBV, 12 weeks | 97.2% (211/217) | ||
SOF/LDV, 24 weeks | NA (n = 217) | ||
SOF/LDV + RBV, 24 weeks | NA (n = 217) | ||
ION-2 | HCV GT 1 treatment-experienced including 20.0% (88/440) with cirrhosis | SOF/LDV, 12 weeks | 93.6% (102/109) |
SOF/LDV+RBV, 12 weeks | 96.4% (107/111) | ||
SOF/LDV, 24 weeks | 99.1% (108/109) | ||
SOF/LDV+RBV, 24 weeks | 99.1% (110/111) | ||
ION-3 | HCV GT1 treatment-naïve | SOF/LDV, 8 weeks | 94.0% (202/215) |
SOF/LDV + RBV, 8 weeks | 93.1% (201/216) | ||
SOF/LDV, 12 weeks | 95.4% (206/216) |